Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IRDBullishIndustry Newsnews

High materiality8/10

Opus Genetics spikes on positive BEST1 trial results, Phase 3 planned for 2027

Sep 9, 2026, 11:22 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Phase 1/2 data with favorable safety, plus regulatory alignment and a larger TAM suggest sustained upside, though execution risk and later-stage data remain; near-term catalyst around 2027 milestones.

AI summary

What happened, with direct paths to the underlying reporting

Opus Genetics reported positive 3- and 6-month results from the low-dose BIRD-1 cohort for OPGx-BEST1, with visual and structural gains and no safety issues. Regulators aligned on pivotal endpoints; Phase 3 dosing planned for 2027 after manufacturing. Addressable BEST1 market expanded to about 45,400 symptomatic patients, underpinning potentially meaningful commercial upside.

Five patients show visual improvements; four show structural retinal gains.
No serious AEs; FDA meeting finalizes Phase 3 endpoints for 2027 start.
Higher-dose cohort expanding; topline three-month data due Q2 2027.
Addressable BEST1 market grows to about 45,400 symptomatic patients.
IRD up 46.7% to $6.36; hits 52-week high.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.